Aktien Sensor

Alnylam Pharmaceuticals has seen record-breaking growth, with its stock price reaching an all-time high and several major investment firms upgrading their ratings and price targets.

Eurofins Scientific SE’s stock price is rising due to growing demand for personalized medicine, biopharmaceuticals, and advanced testing services.

Kyowa Kirin’s stock price has declined despite the growing demand for urothelial carcinoma therapies, which the company is well-positioned to capitalize on.

QIAGEN NV has exceeded market expectations in its second quarter, leading to a revised revenue forecast of 4-5% growth in 2025.

Sartorius AG’s stock price has remained relatively stable despite the company’s potential for long-term growth in the rapidly expanding cell culture market.

Merck KGaA’s second-quarter results were mixed, with a rise in net profit offset by a decline in EBITDA and a cut in sales growth target.

Johnson & Johnson’s stock price has demonstrated remarkable stability due to its diversified product portfolio, global presence, and commitment to innovation, making it a resilient and attractive investment option.

Regeneron Pharmaceuticals’ stock price target has been significantly boosted by prominent analysts following a strong earnings report, with estimates reaching as high as $695.

Neurocrine Biosciences has reported significant Q2 growth, exceeding market expectations and sending its stock price soaring.

Lonza Group AG, a Swiss life sciences company, is charting a course for growth through strategic partnerships and innovation, despite market volatility.